Seth Klarman’s Cullinan Oncology CGEM Stock Holding History

Seth Klarman’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-429,646	Closed	-$5.51M	–	35
2022 Q3	$5.51M	Sell	429,646 -1,105,914	-72%	-$14.9M	0.1%	33
2022 Q2	$19.7M	Hold	1,535,560	–	–	0.29%	32
2022 Q1	$16.1M	Hold	1,535,560	–	–	0.17%	36
2021 Q4	$22.5M	Sell	1,535,560 -300,000	-16%	-$5.98M	0.22%	36
2021 Q3	$40.2M	Hold	1,835,560	–	–	0.37%	30
2021 Q2	$46.3M	Hold	1,835,560	–	–	0.38%	29
2021 Q1	$71.7M	Buy	+1,835,560	New	+$74.5M	0.57%	30

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIG

American International Group New York $2.93M AUM 12.08% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Seth Klarman's CGEM Position: Q4 2022 in Review

Seth Klarman sold out of Cullinan Oncology (CGEM) in Q4 2022, closing a stake of 429,646 shares — an estimated $5.51M sold.

Seth Klarman first reported a position in CGEM in Q1 2021 and held it in 7 quarters. The position peaked at $71.7M in Q1 2021. 97 funds tracked by Wall St. Rank hold CGEM as of Q4 2022.

Seth Klarman reported no remaining Cullinan Oncology position as of Q4 2022 after selling out during the quarter.
Seth Klarman sold 429,646 Cullinan Oncology shares in Q4 2022, an estimated $5.51M.
Seth Klarman first reported a position in Cullinan Oncology in Q1 2021 and held it in 7 quarters.
Seth Klarman's Cullinan Oncology position peaked at $71.7M in Q1 2021.
97 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2022.

Based on Baupost Group's 13F filing for Q4 2022, filed 13 Feb 2023.